Copenhagen, 2015-06-30 09:16 CEST (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of flexible solutions for RNA analysis, today announced the launch of the ExiLERATE LNA™ qPCR product portfolio for real-time PCR analysis of mRNAs and lncRNAs (long non-codingRNA), marking the latest expansion of a growing portfolio of qPCR reagents and kits.
The ExiLERATE LNA™ qPCR portfolio complements the miRCURY LNA™ PCR product offering for miRNA amplification– a product that was rated best performing among 12 different platforms in a comparative study published in Nature Methods 2014 Aug;11(8):809-15.
ExiLERATE LNA™ qPCR portfolio includes a suite of products supporting a complete sample-to-answer solution including sample isolation, cDNA generation and reagents needed for real-time PCR amplification and detection. The portfolio includes a number of pre-validated endogenous controls and a validated assay-design pipeline to support custom assays. Focus has been on developing a highly sensitive and specific system with particular focus on the cDNA synthesis. Proprietary technology enables cDNA synthesis at elevated temperatures thereby overcoming challenging secondary structures and high GC content.
Modern RNA discovery begins with Next Generation Sequencing which has revealed a significantly more complex transcriptome than originally anticipated. This drives a growing demand for custom qPCR assays to validate new transcripts or variants of transcripts. To accommodate this demand, Exiqon has developed an assay design engine for effortless design of custom assays. The assay design tool is available at Exiqon’s cloud-computer environment, XploreRNA (www.xplorerna.com), or at Exiqon’s homepage (www.exiqon.com/LNA-qPCR).
“We are excited to continuously expand our product offering within qPCR to address customer needs. This product offering completes our portfolio and we are now able to support LNA™ enhanced qPCR detection of any RNA, including short and long RNAs.” said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller
The ExiLERATE LNA™ qPCR products are compatible with all major real-time PCR instruments.
Additional information on ExiLERATE LNA™ qPCR products is available at www.exiqon.com/LNA-qPCR
Additional information
Lars Kongsbak, Presidents and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, SVP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)
About Exiqon
Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for RNA analysis used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics develops novel molecular diagnostic tests for early detection of cancer and treatment selection for patients based on gene activity analysis, using the tools developed by Exiqon Life Sciences. Exiqon is listed on the NASDAQ in Copenhagen. For more information about us, please visit www.exiqon.com